Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
Danielle Rinck MDa, Elaine Siegfried MDb
aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO
J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888
A previously healthy 3-year-old boy presented to our Pediatric Derm …
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
Danielle Rinck MDa, Elaine Siegfried MDb
aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO
J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888
A previously healthy 3-year-old boy presented to our Pediatric Derm … Continue reading "Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy"
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale … 
Patients with skin of color are at significantly higher risk of developing keloid scars compared with their fair-skinned counterparts. At the 2022 Skin of Color Update, Dr. Eva Kerby, Assistant Dermatology Professor at Weill Cornell Medicine, and Dr. Maritza Perez, Professor of Dermatology at the University of Connecticut, shared their pathogenesis-informed medical and procedural treatment strat … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 